Pharma & healthcare stocks Valuation research

Biocon fair value — the biosimilars bet

Biocon pioneered Indian biotech and now sells biosimilars — copies of complex biological drugs — worldwide. Big acquisitions brought scale and debt.

FairStocks Research
Updated 16 Nov 2026 · 4 min read
| NSE: BIOCON ₹364
On this page ▾
  1. The business
  2. What the market assumes
  3. The ten-year record
  4. How it is valued
  5. What decides the value
  6. What could go wrong
  7. The full valuation
  8. Questions
Biocon (BIOCON) fair value — is it overvalued? Price ₹364, P/E 131.4, P/B 1.74, ROE —. Based on 10 years of reported financials. FairStocks.
Biocon at a glance. Share price, P/E, P/B and the ten-year revenue trend, from filed accounts. Updated 16 Nov 2026.
In 30 seconds

The market expects Biocon to carry on much as it has.

At today’s share price, buyers are assuming Biocon grows about 16% a year, forever. Over the last ten years it actually grew about 19% a year. The two are close, so the share price does not need the business to improve or to stumble. It needs it to keep doing roughly what it already does.

  • How it is valued: Discounted cash flow.
  • What the price assumes: 16% growth, against 19% the model takes from its own record.
  • Ten-year record: Between FY2019 and FY2026, Biocon's revenue went from ₹5,514 crore to ₹16,927 crore — it compounded at about 17% a year over 7 years.
  • Biggest swing factor: Biosimilar launches. Main risk: Price competition.
Price
₹364
Market cap
₹0.59L Cr
P/E
131.4
P/B
1.74
See Biocon's fair value and the full DCFEvery step of the Biocon working, the scenarios and the report Free during launch →

01India's biotech pioneer

Biocon was founded in Bengaluru in 1978 by Kiran Mazumdar-Shaw. Its main business is Biocon Biologics, which makes biosimilars of insulin, cancer and immunology drugs and bought Viatris' biosimilars business in 2022.

It also makes generic APIs and formulations and owns a majority of Syngene International, a listed research and manufacturing services company.

02What the market is assuming

Work backwards from today's share price and you can see what buyers are quietly taking for granted. Here is the growth that price implies for Biocon, next to what the model assumes from the company's own record.

Market expects
16%
growth priced into today's price
Model assumes
19%
growth the model assumes

The further apart these two numbers are, the bigger the bet a buyer at today's price is making.

03Biocon's record, in plain numbers

Between FY2019 and FY2026, Biocon's revenue went from ₹5,514 crore to ₹16,927 crore — it compounded at about 17% a year over 7 years. Net profit fell from ₹1,003 crore to ₹369 crore, about 13% a year — slower than revenue, so margins narrowed. In FY2026 it kept 2.2% of revenue as net profit — its weakest year in the period. The latest year added 10.9% to revenue, well behind its own long-run pace.

Revenue₹0.06L → ₹0.17L Cr
1920212223242526
Earnings per share₹15.3 → ₹2.8
1920212223242526
Return on equity14.6% → 2.2%
20212223242526
Debt to equity0.89 → 0.32
232426

Revenue and earnings per share in ₹, return on equity and leverage as ratios — all from the filed statements.

Revenue and net profit by year (₹ crore)
YearRevenueNet profitMargin
FY20195,5141,00318.2%
FY20206,36787113.7%
FY20217,10684611.9%
FY20228,1847729.4%
FY202311,1746435.8%
FY202414,7561,2988.8%
FY202515,2621,4299.4%
FY202616,9273692.2%

04How Biocon gets valued — and why

Discounted cash flow

This business is valued on the cash it is expected to generate, discounted back at its cost of capital — with growth taken from its own ten-year record rather than from guidance.

05What decides Biocon's value

Biosimilar launches

New products in the US and Europe drive growth.

Debt reduction

Acquisition debt weighs on profit.

Syngene

Its listed stake adds value.

Generics

A steadier, smaller business.

06What could go wrong

  • Price competition. Biosimilar prices fall as rivals enter.
  • Regulatory delays. Approvals and inspections can slip.
  • Leverage. Heavy debt magnifies setbacks.

07What the full Biocon valuation shows

Model value per share
₹0,000
Upside
+00%
Call
XXXX

Sign in free to see the complete Biocon valuation

  • ✓Fair value per share — from a ten-year discounted cash flow, every step shown
  • ✓The Workbench — change revenue growth, the discount rate or terminal growth and watch Biocon's value move
  • ✓Bull, base and bear cases — and exactly which assumptions move between them
  • ✓Peer comparison — against Sun Pharma, Dr Reddy's and other drugmakers
  • ✓Downloadable report — the full write-up, yours to keep
See Biocon's fair value and the full DCF — free
Free during launch · unlimited valuations · no card required

08Questions people ask about Biocon

What are biosimilars?

Near-copies of biological medicines whose patents have expired.

Who founded Biocon?

Kiran Mazumdar-Shaw, in 1978.

What is Syngene?

A listed research and manufacturing services company majority-owned by Biocon.

Is Biocon overvalued?

At ₹364 the market is pricing in roughly 16% sustained growth, against the ~19% its own record supports. That is less than it has delivered — on these numbers the market is asking the business for less than its own record, which usually means it doubts the record repeats.

What is the intrinsic value of Biocon?

It is computed from the filed financial statements using the method that fits this business (discounted cash flow), with every assumption shown alongside the result. The per-share figure and the full working are in the report.

How much debt does Biocon carry?

Debt to equity stands at 0.32, down from 0.89 at the start of the period — the balance sheet is a core input to the cost of capital used here.

About this research

Written by the FairStocks research team from Biocon's filed accounts and last reviewed 5 Oct 2026; the figures refresh as new results are filed. Every valuation uses the method that fits the business and shows its assumptions — see a fully worked example or the valuation guides. Educational research, not investment advice.

See Biocon's fair value and the full DCFUnlock free